Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.

Bradley JS, Armstrong J, Arrieta A, Bishai R, Das S, Delair S, Edeki T, Holmes WC, Li J, Moffett KS, Mukundan D, Perez N, Romero JR, Speicher D, Sullivan JE, Zhou D.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6252-9. doi: 10.1128/AAC.00862-16. Print 2016 Oct.

2.

A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects.

Li J, Learoyd M, Qiu F, Zhu L, Edeki T.

Clin Drug Investig. 2016 Feb;36(2):119-26. doi: 10.1007/s40261-015-0347-x.

PMID:
26649741
3.

An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.

Sunzel M, Learoyd M, Li J, Li Y, Ngo N, Edeki T.

Int J Antimicrob Agents. 2015 Dec;46(6):682-8. doi: 10.1016/j.ijantimicag.2015.09.009. Epub 2015 Oct 22.

PMID:
26545441
4.

Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects.

Das S, Li J, Armstrong J, Learoyd M, Edeki T.

Pharmacol Res Perspect. 2015 Oct;3(5):e00172. doi: 10.1002/prp2.172. Epub 2015 Aug 25.

5.

Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.

Yang L, Sunzel M, Xu P, Edeki T, Wilson D, Li J, Li H.

Int J Clin Pharmacol Ther. 2015 Aug;53(8):681-91. doi: 10.5414/CP202343.

PMID:
26152131
6.

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S.

J Antimicrob Chemother. 2015 Oct;70(10):2862-9. doi: 10.1093/jac/dkv170. Epub 2015 Jul 1.

PMID:
26133566
7.

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers.

Tominaga N, Edeki T, Li J, Learoyd M, Bouw MR, Das S.

J Infect Chemother. 2015 Aug;21(8):551-8. doi: 10.1016/j.jiac.2015.04.006. Epub 2015 Apr 28.

PMID:
26076867
8.

Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.

Edeki T, Kujacic M, Broadhurst H, Li J, Sunzel M.

Br J Clin Pharmacol. 2014 Dec;78(6):1291-7. doi: 10.1111/bcp.12465.

9.

Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential.

Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T, Das S.

Drug Metab Dispos. 2014 May;42(5):932-42. doi: 10.1124/dmd.113.055335. Epub 2014 Mar 10.

PMID:
24616266
10.

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.

Das S, Armstrong J, Mathews D, Li J, Edeki T.

J Clin Pharmacol. 2014 Mar;54(3):331-40. doi: 10.1002/jcph.199. Epub 2013 Oct 22.

PMID:
24150927
11.

International Transporter Consortium commentary on clinically important transporter polymorphisms.

Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):23-6. doi: 10.1038/clpt.2013.12.

PMID:
23778707
13.

PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.

Karara AH, Edeki T, McLeod J, Tonelli AP, Wagner JA.

J Clin Pharmacol. 2010 Apr;50(4):380-91. doi: 10.1177/0091270009344987. Epub 2010 Jan 23.

PMID:
20097935
14.

PhRMA white paper on ADME pharmacogenomics.

Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA.

J Clin Pharmacol. 2008 Jul;48(7):849-89. doi: 10.1177/0091270008319329. Epub 2008 Jun 4. Review.

PMID:
18524998
15.

Induction of cyp3a in primary cultures of human hepatocytes by ginkgolides a and B.

He N, Cai HB, Xie HG, Collins X, Edeki TI, Strom SC.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):632-5.

PMID:
17581220
16.

Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes.

He N, Xie HG, Collins X, Edeki T, Yan Z.

Clin Exp Pharmacol Physiol. 2006 Sep;33(9):813-5.

PMID:
16922812
17.

Erythrocytosis in a scleroderma patient.

Mabo E, Edeki T, Westney GE, Reed JW, Guo X.

Mt Sinai J Med. 2006 May;73(3):620-1.

PMID:
16758101
18.

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

Gustavson LE, Schweitzer SM, Burt DA, Achari R, Rieser MJ, Edeki T, Chira T, Yannicelli HD, Kelly MT.

Clin Ther. 2006 Mar;28(3):373-87.

PMID:
16750452
19.

Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.

Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB.

Clin Pharmacol Ther. 2006 Mar;79(3):186-96. Epub 2006 Feb 17.

PMID:
16513443
20.

A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.

Karyekar CS, Pradhan RS, Freeney T, Ji Q, Edeki T, Chiu W, Awni WM, Locke C, Schwartz LB, Granneman RG, O'Dea R.

J Clin Pharmacol. 2005 Aug;45(8):910-8.

PMID:
16027401
21.

American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation.

Morrow JD, Edeki TI, El Mouelhi M, Galinsky RE, Kovelesky R, Noveck RJ, Preuss C; American Society for Clinical Pharmacology and Therapeutics.

Clin Pharmacol Ther. 2005 Mar;77(3):113-22. No abstract available.

PMID:
15735605
22.
23.

Depression as a risk factor for Alzheimer disease: the MIRAGE Study.

Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L.

Arch Neurol. 2003 May;60(5):753-9.

PMID:
12756140
24.

Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure.

Nzerue CM, Thomas J, Volcy J, Edeki T.

Int J Artif Organs. 2003 Jan;26(1):86-9.

PMID:
12602474
25.

Association between apolipoprotein E genotype and Alzheimer disease in African American subjects.

Graff-Radford NR, Green RC, Go RC, Hutton ML, Edeki T, Bachman D, Adamson JL, Griffith P, Willis FB, Williams M, Hipps Y, Haines JL, Cupples LA, Farrer LA.

Arch Neurol. 2002 Apr;59(4):594-600.

PMID:
11939894
26.

Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.

He N, Zhang WQ, Shockley D, Edeki T.

Eur J Clin Pharmacol. 2002 Feb;57(12):847-51.

PMID:
11936702
27.

Risk of dementia among white and African American relatives of patients with Alzheimer disease.

Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA; MIRAGE Study Group.

JAMA. 2002 Jan 16;287(3):329-36.

PMID:
11790212
28.

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA.

Pharmacogenetics. 2001 Dec;11(9):803-8.

PMID:
11740344
29.

Clinical importance of genetic polymorphism of drug oxidation.

Edeki T.

Mt Sinai J Med. 1996 Oct-Nov;63(5-6):291-300. Review.

PMID:
8898530
30.

Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals.

Edeki T, Dillon-Moore B, He N.

Am J Ther. 1996 Sep;3(9):611-615.

PMID:
11862300
31.

Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans.

Edeki TI, Goldstein JA, de Morais SM, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR.

Pharmacogenetics. 1996 Aug;6(4):357-60. No abstract available.

PMID:
8873222
32.

Increased baseline sway contributes to increased losses of balance in older people following triazolam.

Robin DW, Hasan SS, Edeki T, Lichtenstein MJ, Shiavi RG, Wood AJ.

J Am Geriatr Soc. 1996 Mar;44(3):300-4.

PMID:
8600201
33.

Genetic polymorphism of S-mephenytoin 4'-hydroxylation.

Daniel HI, Edeki TI.

Psychopharmacol Bull. 1996;32(2):219-30. Review.

PMID:
8783891
35.

Antipyrine repeatability and comparison of the powder and capsule formulations.

Edeki T, Turner P.

Int J Clin Pharmacol Ther. 1995 Feb;33(2):70-5.

PMID:
7757313
36.

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors.

Edeki TI, Brase DA.

Drug Metab Rev. 1995;27(3):449-69. Review. No abstract available.

PMID:
8521750
38.

Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.

Edeki T, Johnston A, Li Kam Wa E, Turner P.

Int J Clin Pharmacol Ther. 1994 Mar;32(3):142-6.

PMID:
8205376
39.

Sensitive assay for triazolam in plasma following low oral doses.

Edeki T, Robin DW, Prakash C, Blair IA, Wood AJ.

J Chromatogr. 1992 May 20;577(1):190-4.

PMID:
1400742
40.

Disposition of antipyrine in patients with extensive metastatic liver disease.

Robertz-Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengler HJ.

Eur J Clin Pharmacol. 1992;42(5):465-9.

PMID:
1606991
41.

Tolerability and kinetics of intravenous medifoxamine in healthy volunteers.

Saleh S, Johnston A, Edeki T, Turner P.

Int Clin Psychopharmacol. 1990 Apr;5(2):97-102.

PMID:
2380545
42.

The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers.

al-Sereiti MR, Edeki T, Lledo P, Turner P.

Int J Clin Pharmacol Res. 1990;10(6):339-45.

PMID:
2099359
43.

An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Edeki T, Johnston A, Turner P.

Eur J Clin Pharmacol. 1990;39(4):405-7.

PMID:
2076727
44.

Hemodialysis clearance of chloroquine in uremic patients.

Akintonwa A, Odutola TA, Edeki T, Mabadeje AF.

Ther Drug Monit. 1986;8(3):285-7.

PMID:
3750371

Supplemental Content

Support Center